To get through a dense jungle, you'll need to clear a path. Similarly, to get past a thick network of scaffolding that often prevents drugs from reaching cancer cells, UCLA researchers have developed nanoparticles capable of clearing a path for drugs to pass through to a tumor.
After continuing to lose money in its fiscal 2013 third quarter, Trovagene insists it is poised to start generating revenue and results through new licensing, R&D partnerships and the launch of a precedent-setting urine-based cancer mutation-monitoring test.
California's GenapSys grabbed $37 million in new Series B financing to help advance development and commercialization of its next-generation genomic sequencing technology.
Researchers have developed a drug-carrying nanoparticle with a dual-surface structure that can play multiple roles in cancer treatment including diagnosis, fluorescent signaling and chemotherapy delivery.
To safely deliver the very powerful anti-cancer compound staurosporine (STS), researchers at the University of California, San Diego School of Medicine have developed a liposome-based method to stabilize the drug and encapsulate it on its way to cancerous cells. STS, originally isolated from a bacterium in 1977, according to a UCSD report, causes apoptosis, or cell death, and for more than 35 years has been too strong for use as a cancer drug.
The Icahn School of Medicine at Mount Sinai in New York will team with a Massachusetts biopharmaceutical company to develop new diagnostics and drugs for cancer, plus central nervous system and endocrine disorders.
As the succession of late-phase cancer vaccine flops shows, critical gaps in knowledge of the disease remain. Failure to tackle these gaps in breast cancer could see the loss of around 185,000 lives in the United Kingdom by 2030.
Quintiles has kicked off a study to determine whether early genomic profiling of cancer patients can help inform physician decisions and match the right participant with the right study, a method the CRO said could speed up the development process of personalized drugs.
Canadian startup ChipCare nailed down nearly $2 million in angel funding to advance a handheld analyzer that could boost access to everything from HIV testing to cancer diagnostics.
Video games have been gaining momentum in healthcare because of various patient benefits, and Genentech's foundation has awarded grant money to propel more games about fighting cancer into the hands of pediatric patients, Medical Marketing & Media reported.